GlassScriptPhysician profile
Chrishawna D Schieber
NPI 1255827374
$675.03
in general payments reported to CMS, 2019-2025
11 companies · $64.47 in 2025
The $64.47 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.78 · 2023: $328 · 2024: $267 · 2025: $64.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $104.48 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $97.90 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $69.66 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $65.68 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $65.44 | 2022-2024 | Evenity, Prolia |
| Abbvie INC. | $63.77 | 2023-2024 | |
| Dexcom, INC. | $60.42 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $38.53 | 2023-2024 | |
| Astellas Pharma US INC | $37.67 | 2023 | Veozah, Myrbetriq |
| Abbott Laboratories | $35.82 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $35.66 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrishawna Schieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.